A passion to help patients and our curiosity to find new ways to treat disease drive our approach to strategic partnerships, with companies who are at the forefront of innovation in drug development.
The ground-breaking work undertaken by teams of research scientists to discover new drugs is only the start of a long and complex journey. It can take years to turn that work into treatments that reach patients.
At Mundipharma, we believe in the power of partnership, collaboration, the strength of trust, and the potential of a shared vision.
With our partners, we achieve more than we ever could alone. We can reach more patients and help more people when it matters most.
Unlocking the potential of scientific discovery
At Mundipharma, we have experience in late-phase development and in leading global, multi-centre clinical trials in a specialty care setting.
In addition, we have a track record of successful marketing authorisations, and capabilities in commercial, manufacturing and supply. With a global reach, we work collaboratively to enable patients to benefit from our partners’ innovation.
Partnerships to bring innovative treatments for challenging health conditions
We are proud to work with many partners to bring innovative medicines to help treat some of the world’s most challenging health conditions.
According to the World Health Organization, asthma is estimated to affect more than 262 million people globally.1 flutiform® (fluticasone propionate/formoterol fumarate), a combination steroid and long-acting beta agonist therapy for the treatment of asthma is a product that Mundipharma has licensed from, and jointly developed with our partner Vectura, a specialist inhalation contract development and manufacturing organisation. Together, we have built a global business providing access to this therapy in over 30 countries, with future launches planned.
Mundipharma and Vectura have announced plans to reformulate flutiform® as a commitment to reducing the product’s carbon footprint.
1. World Health Organization, https://www.who.int/news-room/fact-sheets/detail/asthma. Last accessed 30 October 2024.
Pralatrexate, tradenames FOLOTYN® and DIFOLTA®, was approved by the FDA in September 2009 as the first monotherapy drug for patients with relapsed or refractory T-cell lymphoma, a rare type of blood cancer.
In 2011, we partnered with Allos Therapeutics to bring this orphan drug to markets outside of the US. We were pleased to continue this partnership with Spectrum Pharmaceuticals when they acquired Allos in 2012, and now today with Acrotech Biopharma who acquired a number of Spectrum’s products in 2019.
During this time, we have achieved marketing authorisations from more than 20 countries, including in China and Japan where we conducted Phase 3 studies, helping address unmet need in rare cancers which have a poor prognosis.
The use of Mundipharma biosimilars has resulted in estimated savings of €1 billion to European healthcare systems since their launch.1 Biosimilars play an increasingly important role in providing cost-effective treatment options that enable broad access to effective therapies. We are committed to improving access to healthcare and to bringing new treatments to market at an affordable cost to providers.
In 2019, we launched Pelmeg® (pegfilgrastim).2
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.yellowcard.mhra.gov.uk for how to report side effects.
- Data-on-File. MBL/Biosimilars-001. January 2020.
- Mundipharma launches Pelmeg® (pegfilgrastim), biosimilar in Europe. Press release. Mundipharma. https://mundipharma.eu/2019/02/07/mundipharma-launches-pelmeg%E2%96%BCpegfilgrastim-biosimilar-in-europe/ (Accessed October 2024).
The power of partnership to address unmet patient need
Fungal infections are silent killers claiming the lives of more than 1.6 million people globally every year1.
Fungal disease kills three times more people than malaria.1 Patients critically ill in hospitals or with compromised immune systems are at highest risk of developing a serious fungal infection,1 but despite existing treatments these infections are sadly fatal in up to 40% of patients.2 There are also some limitations with current treatments such as drug-drug interactions, toxicities, low or variable exposure, daily intravenous administration and increasing resistance to treatment which can complicate therapy in a vulnerable population.3,4
Mundipharma launched REZZAYO® (rezafungin), a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults, across Europe in 2024. Subsequently Mundipharma acquired all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area.
Reference:
- Bongomin F, Gago S, Oladele RO et al. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017;3(4).
- Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015; 373:1445-1456.
- Yu Y, Albrecht K, Groll J et al. Innovative therapies for invasive fungal infections in preclinical and clinical development. Expert Opinion on Investigational Drugs 2020.
- Gintjee TJ, Donnelley MA, Thompson GR. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. J. Fungi 2020, 6, 28:
Dedicated Alliance Management team
At Mundipharma, we work with organisations who share our care and commitment to make a difference to patients when it matters most. Our Alliance Management team is dedicated to working with our partners to achieve the best outcome of the alliance for our organisations and for our customers and patients.
Interested in partnering with us?
We establish long-term relationships with companies who share our commitment to bring innovative treatments to patients around the world.
If you would like to talk to us in confidence about becoming a strategic partner, please contact our Business Development team.
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.